on SARTORIUS STED BIO (EPA:DIM)
Sartorius Stedim Biotech presents robust results for 2025
Sartorius Stedim Biotech has reported impressive results for the first nine months of 2025. Sales reached €2,195 million, up 10.2% at constant exchange rates. This growth was largely driven by increased sales of high-margin consumables.
Current EBITDA grew remarkably by 21.0%, reaching €683 million with an increased margin of 31.1%. Net income showed a significant increase of 34.3%, reaching €320 million.
All regions contributed positively, with notable increases in the Americas and Asia/Pacific. Management is optimistic for 2025, revising its guidance upwards with revenue growth expectations of approximately 9%.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SARTORIUS STED BIO news